NextGen Pulmocore 20 gene panel- PDL1 22C3
NextGen Pulmocore 20 gene panel- PDL1 22C3** Price
Brief Details
What Is a NextGen Pulmocore 20 Gene Panel – PDL1 22C3?
The NextGen Pulmocore 20 Gene Panel – PDL1 22C3 is an advanced molecular diagnostic test that combines two important analyses in lung cancer care. It uses next-generation sequencing technology to examine 20 specific genes in your tumour tissue for genetic changes that drive cancer growth. The PDL1 22C3 component measures a specific protein on cancer cells that helps determine if immunotherapy treatments might work for you.
This comprehensive test helps doctors understand the unique genetic fingerprint of your lung cancer to create the most effective personalised treatment plan.
What Does the NextGen Pulmocore 20 Gene Panel – PDL1 22C3 Measure?
This test provides detailed information about your tumour's characteristics to guide treatment decisions:
- Genetic mutations in key genes that commonly drive lung cancer growth.
- Gene fusions where parts of different genes join together abnormally.
- Copy number variations, where genes are duplicated or deleted.
- PD-L1 protein levels on cancer cells influence the immune system response.
- Treatment targets for personalised therapy selection.
NextGen Pulmocore 20 Gene Panel – PDL1 22C3: Who Needs It and Why It's Done
What Symptoms May Call for a NextGen Pulmocore 20 Gene Panel – PDL1 22C3?
This test is not ordered based on initial symptoms but is performed after a lung cancer diagnosis. However, the symptoms that may initially lead to lung cancer detection include:
- Persistent cough that doesn't improve or worsens over time
- Coughing up blood or rust-coloured sputum
- Chest pain that becomes worse with deep breathing or coughing
- Shortness of breath or wheezing without a clear cause
- Hoarseness or changes in your voice
Who Should Get a NextGen Pulmocore 20 Gene Panel – PDL1 22C3?
This specialised test is recommended for specific patient groups:
- Patients with a confirmed non-small cell lung cancer diagnosis.
- Individuals with advanced or metastatic lung cancer.
- Patients whose cancer has spread to other parts of the body.
- Those requiring personalised treatment planning for optimal outcomes.
Why Is a NextGen Pulmocore 20 Gene Panel – PDL1 22C3 Done?
This test transforms lung cancer treatment from a generalised approach to highly personalised medicine, helping doctors select targeted therapies that specifically attack your tumour's unique characteristics for better outcomes.
Importance of a NextGen Pulmocore 20 Gene Panel – PDL1 22C3
The NextGen Pulmocore 20 Gene Panel – PDL1 22C3 is clinically vital because it revolutionises lung cancer treatment by identifying specific genetic alterations that can be targeted with precision medicines. Research shows that patients with certain mutations, like EGFR or ALK, have significantly better outcomes when treated with drugs specifically designed for their tumour type.
The test guides both targeted therapy and immunotherapy decisions, helping doctors choose treatments that are more likely to be effective while potentially reducing unnecessary side effects compared to standard chemotherapy approaches.
NextGen Pulmocore 20 Gene Panel – PDL1 22C3 Booking & Reports – Metropolis Healthcare India
How to Book a NextGen Pulmocore 20 Gene Panel – PDL1 22C3?
- Simple Online Booking
Booking can be done through the Metropolis Healthcare App or website. Select the 'NextGen Pulmocore 20 Gene Panel – PDL1 22C3', choose a convenient time slot, and visit the nearest Metropolis Lab.
- Sample Tracking Updates
Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website.
- Accurate Laboratory Testing
Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results.
- Quick & Easy Reports
Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app.
Is Home Sample Collection for the NextGen Pulmocore 20 Gene Panel – PDL1 22C3 Available Near You?
No, home sample collection is not available for the NextGen Pulmocore 20 Gene Panel – PDL1 22C3, as this test requires tissue samples collected through biopsy procedures. However, Metropolis Healthcare offers convenient sample processing and expert analysis at our NABL & CAP accredited laboratories. Our team coordinates with your healthcare provider to ensure your tissue samples are properly handled and analysed with the highest standards of accuracy and reliability.
How Long Does It Take to Get a NextGen Pulmocore 20 Gene Panel – PDL1 22C3 Report?
Reports are usually available within 4 weeks once the sample reaches the pathology lab.
Note: Reporting time may vary depending on your location.
Where Can I See or Get NextGen Pulmocore 20 Gene Panel – PDL1 22C3 Results?
Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab.
Interpreting NextGen Pulmocore 20 Gene Panel – PDL1 22C3 Results
What Your NextGen Pulmocore 20 Gene Panel – PDL1 22C3 Results May Indicate
The results provide specific information about genetic alterations and protein expression in your tumour:
|
Parameter |
Result Type |
Treatment Implications |
|
Gene Mutations (EGFR, ALK, ROS1, etc.) |
Detected/Not Detected |
Guides targeted therapy selection |
|
Gene Fusions |
Present/Absent |
Identifies specific fusion proteins for targeted treatment |
|
Copy Number Variations |
Amplified/Normal/Deleted |
Indicates gene dosage alterations affecting treatment response |
Conditions that May Affect NextGen Pulmocore 20 Gene Panel – PDL1 22C3 Accuracy
Several factors can influence the accuracy of your test results:
- Tissue quality: Poorly preserved or inadequate tissue samples may affect analysis.
- Tumour content: Samples with low tumour cell percentage may yield inconclusive results.
- Prior treatments: Previous chemotherapy or radiation may alter genetic material.
- Sample age: Older tissue blocks may have degraded DNA, affecting sequencing quality.
- Fixation methods: Improper tissue preservation techniques can impact genetic analysis.
- Contamination: Normal tissue mixed with tumour cells may dilute results.
How Is a NextGen Pulmocore 20 Gene Panel – PDL1 22C3 Done?
The test involves several carefully coordinated steps to analyse your tumour tissue:
- Tissue collection: A biopsy is performed to obtain tumour tissue during diagnosis.
- Sample preparation: Tissue is processed into formalin-fixed paraffin-embedded blocks.
- DNA extraction: Genetic material is carefully extracted from tumour cells.
- Next-generation sequencing: Advanced technology reads the DNA sequence of genes.
- Protein analysis: PD-L1 expression is measured using immunohistochemistry.
- Data analysis: Sophisticated software identifies mutations, fusions, and copy number changes.
- Report generation: Results are compiled into a comprehensive treatment-guiding report.
How Should You Prepare for a NextGen Pulmocore 20 Gene Panel – PDL1 22C3?
Since this test analyses tissue already collected during your biopsy, no special preparation is needed for the laboratory analysis itself:
- No fasting required: The test analyses tissue samples, not blood.
- No dietary restrictions: Your eating habits don't affect tissue genetic analysis.
- Continue medications: Unless specifically advised otherwise by your doctor.
- Provide a complete medical history: Share all relevant clinical information with your healthcare team.
- Bring histopathology reports: Ensure your doctor has access to previous biopsy results.
Diseases that the NextGen Pulmocore 20 Gene Panel – PDL1 22C3 Can Help Detect
This comprehensive molecular analysis helps characterise and guide treatment for several lung cancer types:
- Non-small cell lung cancer (adenocarcinoma, squamous cell carcinoma)
- Lung adenocarcinoma with specific genetic mutations
- Advanced or metastatic lung cancers requiring targeted therapy
- Treatment-resistant lung cancers that need alternative therapeutic approaches
- Recurrent lung cancers where initial treatments have failed
NextGen Pulmocore 20 Gene Panel – PDL1 22C3/Packages that You Can Book With Metropolis Healthcare
Metropolis Healthcare offers comprehensive lung cancer diagnostic solutions to support your complete care journey:
|
Test/Package Name |
Purpose/Highlights |
|
Comprehensive molecular profiling for non-small cell lung cancer |
|
|
Specific ALK gene rearrangement testing for targeted therapy selection |
|
|
Tuberculosis detection and drug resistance testing for differential diagnosis |
Frequently asked questions
Find quick answers to the most common questions about health tests, bookings, and reports.
Regular exercise, a balanced diet, avoiding smoking, maintaining a healthy weight, and managing stress all help reduce heart disease risk.
Common signs include irritability, trouble sleeping, headaches, difficulty concentrating, and muscle tension.
Ratings & Reviews
We're satisfying our customers every day since 1980.
Choose precision On time, every time!
- 98% on time collections with a 60 minutes promise
- Real-time tracking of phlebotomist arrival and report generation
- Fully digital report delivery—view from mobile or desktop instantly
- Continuous monitoring of turnaround times to ensure accuracy and speed
- Dedicated support team to resolve any delays or queries quickly
Why Metropolis Healthcare?
Metropolis has been present for over 40 years in the market.
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
0
Years of experience
170+
Advanced Labs
Trusted by
Leading Doctors & Hospitals
2,000+
Scientific Officers
Proficiency Testing
for Accurate Reports
Latest Blogs & News
Stay informed with our expert insights and updates.
About Us
Metropolis Healthcare is a leading diagnostic service provider in India. We are a team of dedicated professionals committed to ensuring you and your family receive the most accurate and timely healthcare solutions. We believe in making health care accessible, affordable and evidence-based. Our expert panel are equipped with the latest technology and manned by a certified team of over 4000+ technicians.
In diagnostic services, we have more than three decades of experience servicing diverse stakeholders health advantage packages for men, women and seniors, genetic fitness & corporation in over 650+ tests like Oncology, Neurology, Gynaecology, Haematology, and many more. Our diagnostic services are located in leading doctors and clinics and serve over 15+ cities in India.